TrueBinding

TrueBinding is a private, clinical-stage biotech developing a novel therapeutic platform centered on inhibiting Galectin-3, a master regulator of chronic inflammation and age-related decline. Its lead candidate, TB006, has shown early signals of efficacy in a Phase 1b/2a Alzheimer's trial and is advancing into Phase 2 studies for both Alzheimer's and Parkinson's, supported by an FDA-authorized Expanded Access Program. The company's strategy positions it at the intersection of neurodegeneration and the broader biology of aging, aiming to address multiple chronic diseases with a single biologic mechanism. With a lean, experienced leadership team and a platform validated by recent foundational science awards, TrueBinding is pursuing a high-risk, high-reward path in a field of significant unmet need.

Proprietary TrueBinding™ discovery platform focused on 'Master Switches' of aging and disease, primarily Galectin-3 (Gal-3). Develops monoclonal antibodies to neutralize Gal-3, a key driver of chronic inflammation (inflammaging), protein aggregation, and tissue damage.

In Alzheimer's, TrueBinding competes with approved anti-amyloid antibodies (e.g., Leqembi, Kisunla) and a pipeline of therapies targeting tau, neuroinflammation, and other pathways. In Parkinson's, competition includes established symptomatic treatments and emerging disease-modifying candidates. Its broad healthspan platform approach is unique but faces indirect competition from companies targeting specific aging mechanisms (senolytics, mTOR inhibitors).